Modulight Biotherapeutics Secures $12.2M Seed Round

Why It Matters

The capital positions Modulight to advance its first‑in‑class optogenetic therapies, potentially creating a new treatment class for neurological diseases. Success could spur further funding and innovation across the neuro‑tech sector.

Deal Summary

Modulight Biotherapeutics announced the closing of a $12.2 million seed round to fund its optogenetic platform for neurological disorders. The round was led by Jibe Ventures and LocalGlobe, with participation from several other venture firms, accelerating development toward clinical trials.